Perspective on National Coverage Analysis of CAR-T Therapies
Potential strategies for CMS's evaluation of coverage and payment for the various CAR-T therapies are laid out.
Originally published on 10/11/2018 in New England Journal of Medicine
Even if CMS found CAR-T to provide a net benefit for Medicare patients, it could limit who can provide the therapy, require the collection of further outcome data, limit coverage to clinical trials, and design a payment approach promoting price competition.
Read the full article here.